Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R B Rothman

Showing results (141-150 of 262) with videos related to

Pageof 27
Sort By:
Molecular Pharmacology|March 1, 1985
A quantitative study of [3H]D-Ala2-D-Leu5-enkephalin binding to rat brain membranes. Evidence that oxymorphone is a noncompetitive inhibitor of the lower affinity delta-binding siteR B Rothman, W D Bowen, M Herkenham, et al.
Synapse (New York, N.Y.)|April 15, 2000
Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implicationsM H Baumann, M A Ayestas, C M Dersch, et al.
Synapse (New York, N.Y.)|April 20, 2001
Opioid peptide receptor studies. 15. Relative efficacy of 4-[(N-allyl-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide and related compounds at the cloned human delta-opioid receptorH Xu, Y F Lu, J B Thomas, et al.
Neuropharmacology|September 1, 1990
Pretreatment of rats with the irreversible mu-receptor antagonist, beta-FNA, fails to prevent naltrexone-induced upregulation of mu-opioid receptorsR B Rothman, J B Long, V Bykov, et al.
NIDA Research Monograph|January 1, 1991
Pseudoirreversible binding of opiates to opioid receptor subtypes in rat brain: a quantitative studyH Xu, C H Kim, Y C Zhu, et al.
Neuropeptides|June 1, 1985
Evidence that the delta-selective alkylating agent, fit, alters the mu-noncompetitive opiate delta binding siteR B Rothman, J A Danks, M Herkenham, et al.
The Journal of Pharmacy and Pharmacology|December 1, 1989
Apparent down-regulation of rat brain mu- and kappa-opioid binding sites labelled with [3H]cycloFOXY following chronic administration of the potent 5-hydroxytryptamine reuptake blocker, clomipramineC Benkelfat, C S Aulakh, V Bykov, et al.
Biological Psychiatry|December 1, 1995
Effects of intravenous cocaine on plasma cortisol and prolactin in human cocaine abusersM H Baumann, T M Gendron, K M Becketts, et al.
Annals of the New York Academy of Sciences|November 21, 2000
Methamphetamine dependence: medication development efforts based on the dual deficit model of stimulant addictionR B Rothman, J S Partilla, C M Dersch, et al.
Journal of Medicinal Chemistry|December 22, 2000
Synthesis and transporter binding properties of bridged piperazine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909)Y Zhang, R B Rothman, C M Dersch, et al.
Pageof 27

Showing results (141-150 of 262) with videos related to

Sort By:
Pageof 27
Molecular Pharmacology|March 1, 1985
A quantitative study of [3H]D-Ala2-D-Leu5-enkephalin binding to rat brain membranes. Evidence that oxymorphone is a noncompetitive inhibitor of the lower affinity delta-binding siteR B Rothman, W D Bowen, M Herkenham, et al.
Synapse (New York, N.Y.)|April 15, 2000
Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implicationsM H Baumann, M A Ayestas, C M Dersch, et al.
Synapse (New York, N.Y.)|April 20, 2001
Opioid peptide receptor studies. 15. Relative efficacy of 4-[(N-allyl-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide and related compounds at the cloned human delta-opioid receptorH Xu, Y F Lu, J B Thomas, et al.
Neuropharmacology|September 1, 1990
Pretreatment of rats with the irreversible mu-receptor antagonist, beta-FNA, fails to prevent naltrexone-induced upregulation of mu-opioid receptorsR B Rothman, J B Long, V Bykov, et al.
NIDA Research Monograph|January 1, 1991
Pseudoirreversible binding of opiates to opioid receptor subtypes in rat brain: a quantitative studyH Xu, C H Kim, Y C Zhu, et al.
Neuropeptides|June 1, 1985
Evidence that the delta-selective alkylating agent, fit, alters the mu-noncompetitive opiate delta binding siteR B Rothman, J A Danks, M Herkenham, et al.
The Journal of Pharmacy and Pharmacology|December 1, 1989
Apparent down-regulation of rat brain mu- and kappa-opioid binding sites labelled with [3H]cycloFOXY following chronic administration of the potent 5-hydroxytryptamine reuptake blocker, clomipramineC Benkelfat, C S Aulakh, V Bykov, et al.
Biological Psychiatry|December 1, 1995
Effects of intravenous cocaine on plasma cortisol and prolactin in human cocaine abusersM H Baumann, T M Gendron, K M Becketts, et al.
Annals of the New York Academy of Sciences|November 21, 2000
Methamphetamine dependence: medication development efforts based on the dual deficit model of stimulant addictionR B Rothman, J S Partilla, C M Dersch, et al.
Journal of Medicinal Chemistry|December 22, 2000
Synthesis and transporter binding properties of bridged piperazine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909)Y Zhang, R B Rothman, C M Dersch, et al.
Pageof 27